当前位置：
X-MOL 学术
›
medRxiv. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiovascular events associated with CDK4/6 inhibitors based on randomized controlled trials or cohort trials: a safety meta-analysis
medRxiv - Oncology Pub Date : 2024-04-04 , DOI: 10.1101/2024.03.29.24305099 Chengrong Zhang , Guoshuang Shen , Shengmei Li , Fei Ma , Huihui Li , Yuyao Tang , YongXin Li , Zhoujuan Li , Zijun Zhu , Tianlei Qiu , Zhilin Liu , Yi Zhao , Shifeng Huang , Fuxing Zhao , Fanzhen Kong , Jiuda Zhao
medRxiv - Oncology Pub Date : 2024-04-04 , DOI: 10.1101/2024.03.29.24305099 Chengrong Zhang , Guoshuang Shen , Shengmei Li , Fei Ma , Huihui Li , Yuyao Tang , YongXin Li , Zhoujuan Li , Zijun Zhu , Tianlei Qiu , Zhilin Liu , Yi Zhao , Shifeng Huang , Fuxing Zhao , Fanzhen Kong , Jiuda Zhao
Background CDK4/6 inhibitors is highly valued, but the incidence of cardiovascular events (CVAEs) associated with CDK4/6 inhibitors is not clear.
中文翻译：
基于随机对照试验或队列试验的与 CDK4/6 抑制剂相关的心血管事件：安全性荟萃分析
背景CDK4/6 抑制剂受到高度重视，但与 CDK4/6 抑制剂相关的心血管事件 (CVAE) 的发生率尚不清楚。
更新日期：2024-04-07
中文翻译：
基于随机对照试验或队列试验的与 CDK4/6 抑制剂相关的心血管事件：安全性荟萃分析
背景CDK4/6 抑制剂受到高度重视，但与 CDK4/6 抑制剂相关的心血管事件 (CVAE) 的发生率尚不清楚。
京公网安备 11010802027423号